BE2015C068I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C068I2
BE2015C068I2 BE2015C068C BE2015C068C BE2015C068I2 BE 2015C068 I2 BE2015C068 I2 BE 2015C068I2 BE 2015C068 C BE2015C068 C BE 2015C068C BE 2015C068 C BE2015C068 C BE 2015C068C BE 2015C068 I2 BE2015C068 I2 BE 2015C068I2
Authority
BE
Belgium
Application number
BE2015C068C
Other languages
French (fr)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BE2015C068I2 publication Critical patent/BE2015C068I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BE2015C068C 2002-12-20 2015-12-09 BE2015C068I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20

Publications (1)

Publication Number Publication Date
BE2015C068I2 true BE2015C068I2 (en) 2024-08-08

Family

ID=32685362

Family Applications (3)

Application Number Title Priority Date Filing Date
BE2015C068C BE2015C068I2 (en) 2002-12-20 2015-12-09
BE2015C069C BE2015C069I2 (en) 2002-12-20 2015-12-09
BE2015C067C BE2015C067I2 (en) 2002-12-20 2015-12-09

Family Applications After (2)

Application Number Title Priority Date Filing Date
BE2015C069C BE2015C069I2 (en) 2002-12-20 2015-12-09
BE2015C067C BE2015C067I2 (en) 2002-12-20 2015-12-09

Country Status (28)

Country Link
US (2) US20060251676A1 (en)
EP (1) EP1572233B1 (en)
JP (1) JP5475939B2 (en)
KR (3) KR20120118087A (en)
AP (1) AP2005003347A0 (en)
AR (1) AR042530A1 (en)
AT (1) ATE503492T1 (en)
AU (1) AU2003293942B2 (en)
BE (3) BE2015C068I2 (en)
BR (1) BR0317544A (en)
CA (1) CA2510457C (en)
CY (1) CY1111552T1 (en)
DE (1) DE60336581D1 (en)
DK (1) DK1572233T3 (en)
EA (2) EA200701633A1 (en)
EC (1) ECSP055869A (en)
IL (1) IL169085A (en)
IS (1) IS2811B (en)
MA (1) MA27581A1 (en)
MX (1) MXPA05006764A (en)
MY (1) MY144492A (en)
NO (1) NO20052846L (en)
NZ (1) NZ540811A (en)
OA (1) OA13147A (en)
PL (1) PL215257B1 (en)
PT (1) PT1572233E (en)
TW (1) TWI349557B (en)
WO (1) WO2004056389A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1126876E (en) 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Adjuvant systems and vaccines
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
JP2008502633A (en) * 2004-06-16 2008-01-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine against HPV 16 and HPV 18 and at least one other HPV type selected from HPV 31, 45 or 52
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
EP1879614A2 (en) * 2005-04-26 2008-01-23 GlaxoSmithKline Biologicals S.A. Vaccine
SG159525A1 (en) * 2005-04-26 2010-03-30 Glaxosmithkline Biolog Sa Vaccine
CN101293918B (en) * 2007-04-29 2013-03-27 北京万泰生物药业股份有限公司 Shorten human papilloma virus 16 type L1 protein
BRPI0815818A2 (en) 2007-04-29 2016-08-02 Beijing Wantai Biological Pharmacy Entpr Co Ltd human papilloma virus type 18 truncated l1 protein
CA2754533C (en) * 2009-03-05 2019-07-09 Jenny Colleen Mccloskey Treatment of infection
MX2011013566A (en) * 2009-06-19 2012-06-28 Eyegene Inc Vaccine for cervical cancer.
EP3100049B1 (en) 2014-01-31 2019-11-06 Ulisse Biomed S.R.L. Biosensors for the detection of infection and associated maladies
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
KR102285401B1 (en) 2014-10-24 2021-08-02 에이치피브이백스, 엘엘씨. Cancer and skin lesion treatment
CN107614009A (en) * 2015-06-02 2018-01-19 泰尔茂株式会社 Adjunvant composition containing aluminium and the vaccine combination for including it
US12404306B2 (en) * 2018-03-06 2025-09-02 Precigen, Inc. Human papillomavirus vaccines and uses of the same
KR20200128703A (en) 2018-03-06 2020-11-16 프레시전 인코포레이티드 Hepatitis B vaccine and uses thereof
US11771754B2 (en) * 2018-06-04 2023-10-03 Xiamen University Mutant of L1 protein of human papillomavirus type 18
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (en) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoclonal antibodies
PT1015561E (en) 1997-09-05 2006-11-30 Medimmune Inc In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
WO2000045841A2 (en) * 1999-02-05 2000-08-10 Merck & Co., Inc. Human papilloma virus vaccine formulations
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
HRP20021015A2 (en) * 2000-06-26 2004-02-29 Stressgen Biotechnologies Corp Human papilloma virus treatment

Also Published As

Publication number Publication date
ATE503492T1 (en) 2011-04-15
BR0317544A (en) 2005-11-22
MA27581A1 (en) 2005-10-03
EA009179B1 (en) 2007-12-28
NO20052846L (en) 2005-07-13
AR042530A1 (en) 2005-06-22
AU2003293942A1 (en) 2004-07-14
BE2015C067I2 (en) 2024-08-08
DE60336581D1 (en) 2011-05-12
ECSP055869A (en) 2005-09-20
OA13147A (en) 2006-12-13
JP5475939B2 (en) 2014-04-16
DK1572233T3 (en) 2011-06-27
MXPA05006764A (en) 2005-09-08
WO2004056389A1 (en) 2004-07-08
IL169085A0 (en) 2007-07-04
HK1085378A1 (en) 2006-08-25
NZ540811A (en) 2007-03-30
PL377710A1 (en) 2006-02-06
IS2811B (en) 2012-11-15
MY144492A (en) 2011-09-30
CA2510457C (en) 2011-12-06
BE2015C069I2 (en) 2024-08-08
KR101361769B1 (en) 2014-02-10
EP1572233A1 (en) 2005-09-14
IL169085A (en) 2014-04-30
KR20120123616A (en) 2012-11-08
EA200500834A1 (en) 2006-02-24
CY1111552T1 (en) 2015-08-05
JP2006512413A (en) 2006-04-13
EA200701633A1 (en) 2007-12-28
PL215257B1 (en) 2013-11-29
CA2510457A1 (en) 2004-07-08
US20060251676A1 (en) 2006-11-09
PT1572233E (en) 2011-06-07
EP1572233B1 (en) 2011-03-30
AP2005003347A0 (en) 2005-06-30
TWI349557B (en) 2011-10-01
AU2003293942B2 (en) 2009-12-10
KR20050086924A (en) 2005-08-30
US20050287161A1 (en) 2005-12-29
TW200423957A (en) 2004-11-16
KR20120118087A (en) 2012-10-25
IS7885A (en) 2005-06-09

Similar Documents

Publication Publication Date Title
BE2019C510I2 (en)
BE2018C021I2 (en)
BE2017C049I2 (en)
BE2017C005I2 (en)
BE2016C069I2 (en)
BE2016C040I2 (en)
BE2018C018I2 (en)
BE2016C013I2 (en)
BE2015C078I2 (en)
BE2016C002I2 (en)
BE2015C017I2 (en)
BE2014C053I2 (en)
BE2014C051I2 (en)
BE2014C041I2 (en)
BE2014C030I2 (en)
BE2014C016I2 (en)
BE2014C015I2 (en)
BE2013C063I2 (en)
BE2013C039I2 (en)
BE2011C038I2 (en)
JP2003232645A5 (en)
BE2015C068I2 (en)
BE2013C046I2 (en)
JP2003227884A5 (en)
BR0315835A2 (en)